275 related articles for article (PubMed ID: 23861088)
1. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
[TBL] [Abstract][Full Text] [Related]
2. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
Werner CR; Franz C; Egetemeyr DP; Janke-Maier P; Malek NP; Lauer UM; Berg CP
J Viral Hepat; 2014 May; 21(5):333-40. PubMed ID: 24716636
[TBL] [Abstract][Full Text] [Related]
6. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
Ozeki I; Akaike J; Karino Y; Arakawa T; Kuwata Y; Ohmura T; Sato T; Kamiya N; Yamada I; Chayama K; Kumada H; Toyota J
J Gastroenterol; 2011 Jul; 46(7):929-37. PubMed ID: 21556829
[TBL] [Abstract][Full Text] [Related]
11. VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Di Bisceglie AM; Sulkowski M; Gane E; Jacobson IM; Nelson D; DeSouza C; Alves K; George S; Kieffer T; Zhang EZ; Kauffman R; Asmal M; Koziel MJ
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):761-73. PubMed ID: 24901821
[TBL] [Abstract][Full Text] [Related]
12. Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
Kohjima M; Enjoji M; Yoshimoto T; Yada R; Fujino T; Aoyagi Y; Fukushima N; Fukuizumi K; Harada N; Yada M; Kato M; Kotoh K; Nakashima M; Sakamoto N; Tanaka Y; Nakamuta M
J Med Virol; 2013 Feb; 85(2):250-60. PubMed ID: 23161429
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
14. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
Atsukawa M; Tsubota A; Shimada N; Kondo C; Itokawa N; Nakagawa A; Fukuda T; Matsushita Y; Narahara Y; Osada Y; Yamaguchi H; Nakatsuka K; Iwakiri K; Kawamoto C; Sakamoto C
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):781-7. PubMed ID: 24732752
[TBL] [Abstract][Full Text] [Related]
16. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Montes ML; Nelson M; Girard PM; Sasadeusz J; Horban A; Grinsztejn B; Zakharova N; Rivero A; Durant J; Ortega-Gonzalez E; Lathouwers E; Janssen K; Ouwerkerk-Mahadevan S; Witek J; González-García J
J Antimicrob Chemother; 2016 Jan; 71(1):244-50. PubMed ID: 26483516
[TBL] [Abstract][Full Text] [Related]
18. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Oshita M; Mita E; Ito T; Inui Y; Inada M; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
J Viral Hepat; 2015 Mar; 22(3):254-62. PubMed ID: 25081140
[TBL] [Abstract][Full Text] [Related]
19. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
20. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
Corti G; Salomoni E; Baragli F
Int J Infect Dis; 2014 Feb; 19():85-6. PubMed ID: 24246771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]